Bank Of New York Mellon Corp Outlook Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.87 - $1.33 $311,110 - $475,605	357,598 New	357,598 $386,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $26,477 - $32,707	25,958 Added 7.82%	357,907 $437,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $420 - $928	-462 Reduced 0.14%	331,949 $339,000
Q1 2022 May 11, 2022	BUY	$1.22 - $2.03 $50,759 - $84,460	41,606 Added 14.31%	332,411 $592,000
Q4 2021 Feb 11, 2022	BUY	$1.27 - $2.23 $6,253 - $10,980	4,924 Added 1.72%	290,805 $395,000
Q3 2021 Nov 12, 2021	BUY	$2.12 - $2.76 $113,222 - $147,403	53,407 Added 22.97%	285,881 $621,000
Q2 2021 Aug 11, 2021	BUY	$1.78 - $2.76 $244,374 - $378,917	137,289 Added 144.23%	232,474 $578,000
Q1 2021 May 13, 2021	SELL	$0.94 - $3.31 $7,830 - $27,572	-8,330 Reduced 8.05%	95,185 $214,000
Q4 2020 Feb 09, 2021	BUY	$0.7 - $1.58 $36,859 - $83,198	52,657 Added 103.54%	103,515 $134,000
Q2 2020 Aug 12, 2020	SELL	$0.56 - $1.41 $0 - $1	-1 Reduced -0.0%	50,858 $65,000
Q1 2020 May 06, 2020	BUY	$0.51 - $1.08 $25,938 - $54,927	50,859 New	50,859 $30,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.